Skip to content
Menu

BriaCell Therapeutics Corp. BCTX

Full chart Compare
Set alert

Price alert · BCTX

All alert types
3.06 USD -0.10 (-3.32%)

Regular-session close

3.10 +0.04 +1.31%

After hours · Nov 20, 5:59 PM ET

3.02 Day range 3.20
2.74 52-week range 12.64
YTD
-56.96%
1 year
-56.41%

5D -0.27 (-8.11%)

33.203.403.60MonTueWedThuFri3.06
Market cap
26.72M
EPS (ttm)
-6.97
Shares out
44.20M
Forward P/E
-1.38
YTD return
-56.96%
1-year return
-56.41%
50-day average
0.7918
200-day average
1.27
Enterprise value
9.95M
Volume
109.72K
Avg volume
251.45K
Open
3.14
Previous close
3.17
Day's range
3.02 – 3.20
52-week range
2.74 – 12.64
Beta
1.82
Analysts
Strong Buy
Price target
15.00 (+390.2%)

Key statistics

Free cash flow
-10.83M
Total cash
862.09K
Short % of float
2.13%

Fundamental scorecard

7 of 25 checks passed on BCTX’s reported financials

ValueGrowthProfitabilityHealthDividend

7of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Jul 31, 2026.

Financials — quick view

All financials
BCTX Revenue — quarterly 0
BCTX Net income — quarterly -12.51M
BCTX EPS — quarterly -1.24

Earnings

BCTX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Dec 16, 2024Oct 1, 2024-0.08-0.22-0.14-175.00%
Oct 28, 2024Jul 1, 2024-0.52———
Oct 28, 2024Jul 1, 2024-0.52-0.07+0.45+86.54%
Jun 14, 2024Apr 1, 2024-0.55———
Jun 14, 2024Apr 1, 2024-0.550.11+0.66+120.00%
Mar 18, 2024Jan 1, 2024-0.20-0.71-0.51-255.00%

Upgrades / downgrades

BCTX analyst upgrades and downgrades
DateFirmActionFromTo
Dec 12, 2024HC Wainwright & Co.reitBuyBuy
Dec 3, 2024HC Wainwright & Co.reitBuyBuy
Oct 3, 2024HC Wainwright & Co.reitBuyBuy
Sep 19, 2024HC Wainwright & Co.mainBuyBuy
Sep 11, 2024HC Wainwright & Co.reitBuyBuy
Jun 4, 2024HC Wainwright & Co.reitBuyBuy

About BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Sector
Healthcare
Industry
Biotechnology
Country
Canada
Website
briacell.com

News

Your note

Sign in to keep a note on BCTX — it syncs with the Stock Master app.

Insider holders

BCTX insider holders
InsiderRelationLatest transactionDateShares held
Lustig (Marc)10% Security Holder of IssuerAcquisition or disposition in the public marketFeb 16, 20220

Institution ownership

BCTX institution ownership
Holder% heldSharesValueReported
Lynwood Capital Management Inc.3.61%1,597,750857.83KMar 30, 2024
Vontobel Holding Limited0.18%80,00042.95KSep 29, 2024
HRT Financial LP0.17%74,28639.88KSep 29, 2024
Onyx Bridge Wealth Group, LLC0.11%50,00026.84KSep 29, 2024
Group One Trading, L.P.0.09%37,88520.34KSep 29, 2024
Summit Trail Advisors, LLC0.08%35,00018.79KSep 29, 2024

Fund ownership

BCTX fund ownership
Holder% heldSharesValueReported
Fidelity NASDAQ Composite Index Fund0.02%7,2293.88KOct 30, 2024